Conolidine’s analgesic effects stem from its interaction with non-opioid pain pathways. In contrast to opioids, which bind to µ-opioid receptors inside the central anxious process, conolidine modulates alternate molecular targets. A Science Developments review located that conolidine interacts Using the atypical chemokine receptor ACKR3/CXCR7, w